Raltegravir: Opening the road for integrase inhibitors in clinical practice

Future HIV Therapy

Volumn 2, Issue 3, 2008, Pages 217-227

  Sued, Omar ^a   Cahn, Pedro ^a  

^a FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

HAART; HIV 1 infection therapy; Integrase inhibitors; MK 0518; Raltegravir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; COMPLEMENTARY DNA; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; INTEGRASE INHIBITOR; L 870812; LAMIVUDINE; MARAVIROC; MIDAZOLAM; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANUS CANCER; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FOOD; FOOD DRUG INTERACTION; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INJECTION SITE REACTION; KAPOSI SARCOMA; LIPODYSTROPHY; LIVER CELL CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME;

EID: 52349083875     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.3.217     Document Type: Article

References (38)

1. Temesgen Z, Cainelli F, Poeschla EM, Vlahakis SA, Vento S: Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis. 6(8), 496-507(2006).
2. Hindmarsh P, Leis J: Retroviral DNA integration. Microbiol. Mol. Biol. Rev. 63(4), 836-843 (1999).
3. Esposito D, Craigie R: HIV integrase structure and function. Adv. Virus Res. 52, 319-333 (1999).
4. Chiu TK, Davies DR: Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4(9), 965-977 (2004).
5. Fesen MR, Kohn KW, Leteurtre F, Pommier Y: Inhibitors of human immunodeficiency virus integrase. Proc. Natl Acad. Sci. USA 90(6), 2399-2403 (1993).
6. Nair V, Chi G: HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 17(4), 277-295 (2007).
7. Goldgur Y, Craigie R, Cohen GH et al.: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA 96(23), 13040-13043 (1999).
8. Hazuda DJ, Anthony NJ, Gomez RP et al.: A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl Acad. Sci. USA 101(31), 11233-11238 (2004).
9. Hazuda DJ, Felock P, Witmer M et al.: Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287(5453), 646-650 (2000).
10. Hazuda DJ, Young SD, Guare JP et al.: Integrase inhibitors and cellular immunity suppress retroviral replication in Rhesus macaques. Science 305(5683), 528-532 (2004).
11. Pommier Y, Johnson AA, Marchand C: Integrase inhibitors to treat HIV/ AIDS. Nat. Rev. Drug Discov. 4 (3), 236-248 (2005).
12. Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev. And. Infect. Ther. 5(1), 67-75 (2007).
13. Iwamoto M, Wenning LA, Perry AS et al.: Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83(2), 293-299 (2007).
14. Wenning L, Anderson M, Perry AS et al.: Raltegravir dose proportionality and effect of food. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2007) (Abstract H-1046).
15. Kassahun K, McIntosh I, Cui D et al.: Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the HIV-1 integrase enzyme. Drug Metab. Dispos. 35(9), 1657-1663 (2007).
16. Petry AS, Hanley H, Silk G et al.: Effect of severe renal insufficiency on raltegravir pharmacokinetics. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2007) (Abstract A-1424).
17. Iwamoto M, Wenning L, Petry A et al.: Minimal effect of ritonavir and efavirenz on the pharmacokinetics of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (2006) (Abstract A-0373).
18. Long K, Soulié C, Schneider L et al.: Therapeutic drug monitoring of raltegravir (MK-0518) in experienced HIV-infected patients. 11th European AIDS Conference. Madrid, Spain (2007) (Abstract ABS021).
19. Wenning LA, Hanley H, Stone J, Moreau J, Kost JT, Mangin E: Effect of tipranavir plus ritonavir on pharmacokinetics of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (2006) (Abstract A-0374).
20. Kumar P, Cooper D, Steigbigel R, Zhao J, Teppler H, Nguyen BY: Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing enfuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from Benchmrk-1 and Benchmrk-2. 11th European AIDS Conference. Madrid, Spain (2007) (Abstract 151).
21. Mistry G, Wenning L, Merschman S et al.: Atazanavir and ritonavir increase plasma levels of MK-0518. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2006) (Abstract P291).
22. Grinsztejn B, Nguyen BY, Katlama C et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369(9569), 1261-1269 (2007).
23. Wenning LA, Friedman E, Kost JT, Merschman S, Lasseter K, Azrolan N: Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (2006) (Abstract A-0375).
24. Iwamoto M, Wenning L, Liou S et al.: Rifampin modestrly reduces plasma levels of MK-0518. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2006) (Abstract P299).
25. Iwamoto M, Wenning L, Troyer M et al.: Lack if a pharmacokinetic interaction of MK-0518 on midazolam. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2006) (Abstract P300).
26. Anderson M, Wenning L, Moreau J et al.: Effect of raltegravir on the pharmacokinetics of oral contraceptives. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2007) (Abstract A-1425).
27. Markowitz M, Morales-Ramirez JO, Nguyen BY et al.: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43(5), 509-515 (2006).
28. Markowitz M, Nguyen BY, Gotuzzo E et al.: Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46(2), 125-133 (2007)
29. Murray JM, Emery S, Kelleher AD et al.: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21(17), 2315-2321 (2007).
30. Grinsztejn B, Nguyen BY, Katlama C et al.: 48 weeks efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2007) (Abstract H-713).
31. Cooper D, Gatell JM, Rockstroh J et al.: Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February, 2007.
32. Steigbigel R, Kumar P, Eron J et al.: Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 Integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007.
33. Cooper D, Gatell J, Rockstroh J et al.: 48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple class resistant HIV-1. Presented at: 15th Conference on Retroviruses and Opportunities Infections. Boston, USA, 3-6 February, 2008.
34. Steigbigel R, Kumar P, Eron J et al.: 48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple class resistant HIV-1. Presented at: 15th Conference on Retroviruses and Opportunities Infections. Boston, USA, 3-6 February, 2008.
35. Hazuda D, Miller MD, Nguyen BY, Zhao J: Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Presented at: XVI International HIV Drug Resistance Workshop. Barbados, 12-16 June, 2007.
36. McColl D, Fransen S, Gupta S et al.: Resistance analysis of a Phase 2 study of the integrase inhibitor elvitegravir (GS-9137). 11th European AIDS Conference. Madrid, Spain (2007) (Abstract ABS014 5).
37. Teague A, Scott C, Bower M, Gazzard B, Nelson M: Clinical experience with raltegravir (MK-0518), with an optimised background regimen in highly treatment-experienced patients. 11th European AIDS conference. Madrid, Spain (2007) (Abstract ABS0155).
38. Harris M, Larsen G, Montaner J: Outcomes of patients switched from enfuvirtide to raltegravir within a virological supressive regimen. 15th Conference on Retroviruses and Opportunistics Infections. Boston, USA, 3-6 February, 2008 (Poster 799).